We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Digital Diagnostic Platform Uses Electronic Technology for Rapid Disease Detection

By LabMedica International staff writers
Posted on 02 Jun 2025

Traditional diagnostic methods often fall short in providing rapid, accurate detection of infectious diseases, leading to delays in treatment and increased transmission. More...

Now, a groundbreaking digital diagnostics platform aims to revolutionize point-of-care testing with real-time, high-sensitivity results.

The platform, developed by IdentifySensors Biologics (Shaker Heights, OH, USA), utilizes advanced graphene-based sensors integrated into a compact, reusable Bluetooth-enabled device. This technology allows for the detection of multiple pathogens from a single saliva sample without the need for enzymatic amplification or reagents, streamlining the diagnostic process. The system comprises a handheld reader and disposable test cartridges capable of identifying up to three pathogens simultaneously. By targeting conserved genomic regions, the platform ensures high specificity and sensitivity, surpassing traditional PCR tests in detecting viral concentrations as low as 200 copies per milliliter.

Preliminary clinical trials have demonstrated approximately 98% accuracy in rapid result delivery from verified COVID-19 samples. Beyond COVID-19, the platform is being developed to detect a broad spectrum of pathogens, including RSV, influenza, norovirus, rotavirus, adenovirus, HIV, hepatitis, chlamydia, gonorrhea, herpes, MRSA, Lyme disease, and tropical diseases like Zika and dengue. Its versatility and rapid turnaround make it a promising tool for both clinical settings and at-home testing, facilitating timely medical interventions and reducing disease spread. IdentifySensors has initiated the FDA review process by submitting a pre-EUA for emergency use authorization of a rapid Ebola test on the company's new Check4 platform.

"This is the new internet of things for diagnostics," said IdentifySensors CEO Greg Hummer. "Current molecular tests are old, slow, expensive and require skilled labor. Our rapid detection platform solves that through electronic circuits that connect instantly to cloud-based algorithms and healthcare software systems."

Related Links:
IdentifySensors Biologics


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hepatitis A Rapid Test
Anti-HAV IgM Rapid Test Kit
New
See-Saw Rocking Shaker
SH-200D-S-L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: INDICAID HPV Urine Test can detect 14 types of high-risk HPV using patented urine DNA concentration technology (Photo courtesy of PHASE Scientific)

World’s First Urine-Based HPV Test to Transform Cervical Cancer Screening

Human papillomavirus (HPV) is a very common sexually transmitted infection (STI) that causes more than 95% of cervical cancer cases. Detection of HPV infections that lead to cellular transformation, followed... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.